USPTO Patent Application for Cancer Prodrugs

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085069A1) for novel prodrug compounds designed to treat cancer and other diseases by inhibiting Casein Kinase 2 alpha (CK2α). The application details specific chemical structures and their potential pharmaceutical uses.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260085069A1) for new prodrug compounds that are inhibitors of Casein Kinase 2 alpha (CK2α). These compounds are intended for the treatment and prevention of various diseases, including cancer, viral infections, inflammation, diabetes, and neurodegenerative disorders. The application specifies chemical structures of Formula II and their use in pharmaceutical compositions.

This is a patent application, not a regulatory rule or guidance. It does not impose new compliance obligations on regulated entities. However, it represents a potential future development in cancer therapeutics, which may be of interest to pharmaceutical companies and researchers in the field. No immediate actions or deadlines are associated with this publication for compliance officers.

Source document (simplified)

← USPTO Patent Applications

PRODRUGS

Application US20260085069A1 Kind: A1 Mar 26, 2026

Inventors

PAUL GLOSSOP

Abstract

Provided are compounds of the Formula II, and salts, hydrates and solvates thereof: wherein R is as defined in the specification. The compounds are prodrugs of inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the prodrugs defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.